KTKaoru Takasaki

Kaoru Takasaki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kaoru Takasaki has a total of 45 co-authors. Here are the top co-authors by number of shared publications:

  • Stella T. Chou

    Department of Pediatrics University of Pennsylvania Philadelphia Pennsylvania USA

    7 shared publications
  • Deborah L. French

    Perelman School of Medicine Philadelphia Pennsylvania USA

    5 shared publications
  • Alyssa Gagne

    Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA, USA

    3 shared publications
  • Sara S. Kumar

    Division of Hematology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, USA

    3 shared publications
  • David Smith

    Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, PA, USA

    2 shared publications
  • Peter A. Gearhart

    Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Obstetrics and Gynecology, Pennsylvania Hospital, University of Pennsylvania Health System, Philadelphia, PA, USA

    2 shared publications

Latest Publications

  • Open Access

    A quantitative dissection of the DNA ‐binding properties of pathogenic GATA1 mutants

    by Kaoru Takasaki

    Transcription factors are modulated by a precisely coordinated set of conditions, including cell context, target sequences and their accessibility, and co‐factor recruitment. Disruption to any of these conditions can dramatically affect transcription factor activity, but quantitatively characterizing the consequences of individual mutations—either in the transcription factors themselves or in their target sequences—has remained a technical challenge. Zambo et al. present an innovation on their native holdup assay that measures DNA–protein binding activity under physiologic or near‐physiologic conditions and use mutant GATA1‐ ATP2B4 binding as an illustrative example. This technique holds promise for uncovering the molecular mechanisms underlying genetically‐driven diseases.

  • Open Access

    Rare antigen‐negative red blood cells from pluripotent stem cells for precision transfusion medicine

    by Naomi Gunawardena, Hyun Hyung An, Randall W. Veliquette, Edmund Carvalho, Sambit Dalui, Kaoru Takasaki, Eric Wafula, Deborah L. French, Giulia Pavani, Stella T. Chou

    Background: Blood bank identification of antibodies against high‐prevalence antigens remains a challenge due to the scarcity of antigen‐negative reagent red cells sourced from blood donors. The MAM antigen, encoded by EMP3 , is one such antigen associated with red cell alloimmunization and hemolytic disease of the fetus and newborn. Study Design and Methods: We used CRISPR‐Cas9 gene editing to generate an EMP3 knockout (EMP3KO) induced pluripotent stem cell (iPSC) line from a type O, Rh null parent line, enabling production of rare MAM‐negative red blood cells. Since a prior study suggested that loss of EMP3 may enhance erythroid proliferation, we hypothesized that EMP3KO could both yield a rare reagent cell and potentially improve erythroid expansion to support scalable production. Transcriptomic analysis allowed us to further investigate the effect of EMP3 loss in late erythroblasts. Results: EMP3KO cells differentiated efficiently into erythroid cells, showing >95% CD235/CD71 co‐expression and orthochromatic erythroblast morphology. Compared to unedited cells, no proliferative advantage was observed, contrasting with prior non‐isogenic cell models. Agglutination assays confirmed complete loss of MAM antigen and demonstrated the diagnostic utility for identifying MAM antibodies. Transcriptomic profiling of EMP3KO erythroblasts revealed expression of key erythroid genes, as well as regulators of proliferation and heme metabolism, was comparable to the parent line. Discussion: This study demonstrates that iPSC technology combined with gene editing can generate rare antigen‐negative RBCs for immunohematology applications. Beyond MAM, this platform offers a strategy to create additional rare RBC phenotypes, advancing precision transfusion medicine and improving antibody identification against high‐prevalence antigens.

  • Open Access

    Single-cell transcriptomics reveal individual and cooperative effects of trisomy 21 and GATA1s on hematopoiesis

    by Kaoru Takasaki, Eric K. Wafula, Jian Meng Fan, Ying Ting Sit, Sara S. Kumar, David Smith, Alyssa Gagne, Peter A. Gearhart, Deborah L. French, Christopher S. Thom, et al.


  • Open Access

    Single-cell transcriptomics reveal individual and synergistic effects of Trisomy 21 and GATA1s on hematopoiesis

    by Kaoru Takasaki, Eric K. Wafula, Sara S. Kumar, David Smith, Alyssa L. Gagne, Deborah L. French, Christopher S. Thom, Stella T. Chou

    Trisomy 21 (T21), or Down syndrome (DS), is associated with baseline macrocytic erythrocytosis, thrombocytopenia, and neutrophilia, as well as transient abnormal myelopoiesis (TAM) and myeloid leukemia of DS (ML-DS). TAM and ML-DS blasts both arise from an aberrant megakaryocyte-erythroid progenitor and exclusively express GATA1s, the truncated isoform of GATA1 , while germline GATA1s mutations in a non-T21 context lead to congenital cytopenia(s) without a leukemic predisposition. This suggests that T21 and GATA1s both perturb hematopoiesis in multipotent progenitors, but studying their individual effects is challenging due to limited access to relevant human progenitor populations. To dissect individual developmental impacts, we used single-cell RNA-sequencing to interrogate hematopoietic progenitor cells (HPCs) from isogenic human induced pluripotent stem cells differing only by chromosome 21 and/or GATA1 status. The transcriptomes of these HPCs revealed significant heterogeneity and lineage skew dictated by T21 and/or GATA1s. T21 and GATA1s each disrupted temporal regulation of lineage-specific transcriptional programs and specifically perturbed cell cycle genes. Trajectory inference revealed that GATA1s nearly eliminated erythropoiesis, slowed MK maturation, and promoted myelopoiesis in the euploid context, while in T21 cells, GATA1s competed with the enhanced erythropoiesis and impaired megakaryopoiesis driven by T21 to promote production of immature erythrocytes, MKs, and myeloid cells. The use of isogenic cells revealed distinct transcriptional programs that can be attributed specifically to T21 and GATA1s, and how they independently and synergistically result in HPC proliferation at the expense of maturation, consistent with a pro-leukemic phenotype.

  • Open Access

    Synergistic roles of DYRK1A and GATA1 in trisomy 21 megakaryopoiesis

    by Ying Ting Sit, Kaoru Takasaki, Hyun Hyung An, Yan Xiao, Christian Hurtz, Peter A. Gearhart, Zhe Zhang, Paul Gadue, Deborah L. French, Stella T. Chou

    Patients with Down syndrome (DS), or trisomy 21 (T21), are at increased risk of transient abnormal myelopoiesis (TAM) and acute megakaryoblastic leukemia (ML-DS). Both TAM and ML-DS require prenatal somatic mutations in GATA1 , resulting in the truncated isoform GATA1s. The mechanism by which individual chromosome 21 (HSA21) genes synergize with GATA1s for leukemic transformation is challenging to study, in part due to limited human cell models with wild-type GATA1 (wtGATA1) or GATA1s. HSA21-encoded DYRK1A is overexpressed in ML-DS and may be a therapeutic target. To determine how DYRK1A influences hematopoiesis in concert with GATA1s, we used gene editing to disrupt all 3 alleles of DYRK1A in isogenic T21 induced pluripotent stem cells (iPSCs) with and without the GATA1s mutation. Unexpectedly, hematopoietic differentiation revealed that DYRK1A loss combined with GATA1s leads to increased megakaryocyte proliferation and decreased maturation. This proliferative phenotype was associated with upregulation of D-type cyclins and hyperphosphorylation of Rb to allow E2F release and derepression of its downstream targets. Notably, DYRK1A loss had no effect in T21 iPSCs or megakaryocytes with wtGATA1. These surprising results suggest that DYRK1A and GATA1 may synergistically restrain megakaryocyte proliferation in T21 and that DYRK1A inhibition may not be a therapeutic option for GATA1s-associated leukemias.


  • Open Access

    Generation of CHOPi-008-B, a euploid iPSC line from a patient with Trisomy 21 and a GATA1 mutation

    by Kaoru Takasaki, Sara S. Kumar, Alyssa Gagne, Deborah L. French, Stella T. Chou


  • Open Access

    Generation of 2 isogenic clones from a patient with Trisomy 21 and a GATA1 mutation

    by Kaoru Takasaki, Sara S. Kumar, Alyssa Gagne, Deborah L. French, Stella T. Chou


  • Variant RHD alleles and Rh immunization in patients with sickle cell disease

    by Kaoru Takasaki, David F. Friedman, Stacey Uter, Sunitha Vege, Connie M. Westhoff, Stella T. Chou

    Summary: RH diversity among patients and donors contributes to Rh immunization despite serologic Rh‐matched red cell transfusions. Anti‐D can occur in D+ patients with RHD variants that encode partial D antigens. Anti‐D has also been reported in patients with conventional RHD transfused primarily with units from Black donors who frequently have variant RHD. We report 48 anti‐D in 690 D+ transfused individuals with sickle cell disease, categorized here as expressing conventional D, partial D or D antigen encoded by RHD*DAU0. Anti‐D formed in a greater proportion of individuals with partial D, occurred after fewer D+ unit exposures, and remained detectable for longer than for those in the other categories. Among all anti‐D, 13 had clinical or laboratory evidence of poor transfused red cell survival. Most individuals with anti‐D were chronically transfused, including 32 with conventional RHD who required an average of 62 D− units/year following anti‐D. Our findings suggest that patients with partial D may benefit from prophylactic D− or RH genotype‐matched transfusions to prevent anti‐D. Future studies should investigate whether RH genotype‐matched transfusions can improve use of valuable donations from Black donors, reduce D immunization and minimize transfusion of D− units to D+ individuals with conventional RHD or DAU0 alleles.


  • Red cell genotyping: Real world use

    by Kaoru Takasaki, Stella T. Chou


  • Open Access

    Andexanet alfa for reversal of rivaroxaban in a child with intracranial hemorrhage

    by Kaoru Takasaki, David Hehir, Leslie Raffini, Benjamin J. Samelson‐Jones, Evelyn Shih, Aleksandra Sarah Dain